Fig. 1
elevated Trp metabolism correlated with drugs resistance in prostate cancer. A, immunohistochemical staining of TDO2 in prostatic tumor tissues from chemo-sensitive (C-S) and chemo-resistant (C-R) patients (n = 10 per groups). B, immunohistochemical staining of Kyn in prostatic tumor tissues from chemo-sensitive (C-S) and chemo-resistant (C-R) patients (n = 10 per groups). C, western blotting of TDO2 in LNCaP/VCaP cells (VEC) and TDO2 overexpression LNCaP/VCaP cells (OE). D, Trp concentration in culture medium of LNCaP/VCaP cells (VEC) and TDO2 overexpression LNCaP/VCaP cells (OE). 105 cells were cultured in 2 ml culture medium for 48 h. E, Kyn concentration in culture medium of LNCaP/VCaP cells (VEC) and TDO2 overexpression LNCaP/VCaP cells (OE). 105 cells were cultured in 2 ml culture medium for 48 h. F, cell apoptosis of LNCaP/VCaP cells (VEC) and TDO2 overexpression LNCaP/VCaP cells (OE) treated with Abi (10 μM). G, cell apoptosis of LNCaP/VCaP cells (VEC) and TDO2 overexpression LNCaP/VCaP cells (OE) treated with Doc (1 μg/ml). H, cell apoptosis of LNCaP/VCaP cells (PBS or 200 μM Kyn cultured) treated with Abi (10 μM). I, cell apoptosis of LNCaP/VCaP cells (PBS or 200 μM Kyn cultured) treated with Doc (1 μg/ml)